#USA #Philadelphia #WCG #Clario #eCOA

Clario's Strategic Acquisition of WCG's eCOA Business

In a significant move to solidify its place as a leader in the clinical trial industry, Clario has successfully completed its acquisition of WCG's electronic Clinical Outcome Assessment (eCOA) business. This acquisition is expected to greatly enhance the company's capabilities in collecting and analyzing data for neuroscience drug development, a critical area where quality data is often in high demand.

Enhancing Capabilities in Neuroscience Trials

The acquisition not only expands Clario's offerings but also reinforces its commitment to providing reliable data across various therapeutic areas. Clario's CEO, Chris Fikry, expressed his enthusiasm about integrating WCG's eCOA team into Clario's operations. He stated, “Along with our recent acquisition of NeuroRx, we're now positioned to lead in delivering endpoint data solutions for neuroscience clinical trials.” This integration is set to give clients access to the most dependable and high-quality data that spans multiple modalities, catering to all major neuroscience endpoints.

The synergy with WCG will further enhance Clario’s extensive capabilities, which include:

• - Study Design and Protocol Development: Tailoring studies to meet specific research needs.
• - Site Selection and Training: Ensuring optimal site performance.
• - Clinical Outcomes Assessments: Offering a framework to evaluate patient-completed data effectively.
• - Centralized Image Analysis: Standardizing image assessments across various trial sites.
• - Cardiac Safety Expertise: Maintaining patient safety during clinical trials.
• - Quantitative Movement Analysis: Providing detailed motion assessments.
• - Regulatory Guidance: Assisting clients through complex approval processes.

A Major Step for Clinical Research

Terry Burke, the Executive Vice President and General Manager of Clario's eCOA business, emphasized the game-changing nature of this acquisition, particularly for clinical research in neuroscience. Burke mentioned that WCG has made significant contributions to eCOA in neuroscience trials. He also reassured clients that trial operations will continue uninterrupted, emphasizing that the integration aims to preserve the strengths of both teams.

“This acquisition not only brings WCG’s flourishing eCOA solutions into Clario’s portfolio, but it also enables us to deliver the necessary high-quality data and scientific rigor required for new complex studies,” Burke added.

A Bright Future Ahead

Clario's acquisition reflects the company's ongoing investment in innovation and growth, as it strives to enhance high-quality clinical trial data solutions. With the backing of prominent private equity firms such as Astorg and Nordic Capital, Clario is well-positioned to continue its trajectory of growth and leadership in clinical trial endpoint solutions.

Judith Charpentier of Astorg and Daniel Berglund from Nordic Capital stated in a joint comment, “We are thrilled about Clario's strategic acquisition of WCG's eCOA business, which will further empower its status as a global leader in clinical trial endpoint solutions.”

In conclusion, Clario's acquisition of WCG's eCOA business represents a notable step forward in the realm of clinical trials, particularly in neuroscience. As the company integrates WCG's expertise and technologies, it aims to deliver unparalleled solutions in clinical endpoint data collection and analysis.

For further information on Clario and their groundbreaking solutions, visit clario.com.